Key Highlights
- Revenue rose approximately 31% YoY to $652.5 million.
- Net loss was $28.4 million, or $0.25 per share.
- Full-year 2026 Revenue guidance raised to $2.6-$2.7 billion.
- Shares closed at $4.60, up $0.35, or 8%, at Tuesday's close.
Evolent Health, Inc. (NYSE:EVH)'s second quarter combined sharply higher revenue and Adjusted EBITDA with a net loss, as its Performance Suite segment grew and the company raised its full-year 2026 outlook. Co-Founder and Chief Executive Officer Seth Blackley said the company's results, updated 2026 guidance and 2027 outlook demonstrate strong growth, profitability and cash flow.
EVH provides specialty care management and technology services to health plans and providers. The company's revenue is organized across Performance Suite, Specialty Tech and Services, and Administrative Services product lines.
The company said it ended the quarter with $115.7 million in cash and cash equivalents and net Debt of $808.3 million.
Second quarter 2026 compared with the first quarter
Total revenue was $652.5 million, up 31% from the first quarter. Performance Suite revenue was $485 million, up 50% from the first quarter. Specialty Tech and Services revenue was $78 million, down 3%, which the company attributed to code review scope changes. Administrative Services revenue was $48 million, down slightly.
Adjusted EBITDA was $28 million, up 27% from the first quarter. Net loss was $28.4 million, or $0.25 per share. The company's medical expense ratio was 95%, against 93% in the first quarter, which it attributed to the impact of its Highmark launch.
Management outlook and stated risks
Management raised its full-year 2026 revenue guidance to a range of $2.6 billion to $2.7 billion, from a prior range of $2.4 billion to $2.6 billion. The company said it expects full-year 2026 medical expense ratio of approximately 93%, with third- and fourth-quarter revenue expected to be higher than the second quarter.
Management said it expects 2027 revenue growth to exceed 25%, with Adjusted EBITDA at or above $150 million at the midpoint, supported by the strength of its renewing Business and continued new business growth. The company said it announced a new oncology Performance Suite Partnership it expects to launch by December 2026, subject to regulatory approvals, and to generate approximately $300 million in annualized revenue.
Investment Takeaway
Management tied its forward plans to launching its new oncology Performance Suite partnership and expanding contracts with regional Blues plans. The company said it continues to see a positive sales environment supporting its raised 2026 and 2027 outlook.






Please wait processing your request...